Baxter International Inc (BAX) Receives $70.23 Average Price Target from Analysts

Baxter International Inc (NYSE:BAX) has been given a consensus rating of “Buy” by the seventeen analysts that are covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $70.23.

Several analysts have commented on BAX shares. Evercore ISI started coverage on shares of Baxter International in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $71.00 target price for the company. Bank of America upgraded shares of Baxter International from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 2nd. Raymond James Financial upgraded shares of Baxter International from a “market perform” rating to an “outperform” rating and set a $73.00 target price for the company in a research report on Wednesday, January 3rd. Stifel Nicolaus reiterated a “hold” rating and set a $65.00 target price on shares of Baxter International in a research report on Thursday, October 26th. Finally, Zacks Investment Research cut shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Tuesday, December 26th.

In other news, SVP Giuseppe Accogli sold 28,641 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $67.00, for a total value of $1,918,947.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jeanne K. Mason sold 33,350 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $65.25, for a total transaction of $2,176,087.50. Following the completion of the transaction, the senior vice president now directly owns 124,609 shares of the company’s stock, valued at approximately $8,130,737.25. The disclosure for this sale can be found here. 0.05% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in the company. Gofen & Glossberg LLC IL grew its holdings in shares of Baxter International by 1.3% in the 2nd quarter. Gofen & Glossberg LLC IL now owns 15,354 shares of the medical instruments supplier’s stock valued at $930,000 after buying an additional 203 shares during the period. Checchi Capital Advisers LLC grew its holdings in shares of Baxter International by 16.5% in the 4th quarter. Checchi Capital Advisers LLC now owns 5,464 shares of the medical instruments supplier’s stock valued at $353,000 after buying an additional 774 shares during the period. DnB Asset Management AS grew its holdings in shares of Baxter International by 1.7% in the 4th quarter. DnB Asset Management AS now owns 54,428 shares of the medical instruments supplier’s stock valued at $3,518,000 after buying an additional 900 shares during the period. DekaBank Deutsche Girozentrale grew its holdings in shares of Baxter International by 0.5% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 185,750 shares of the medical instruments supplier’s stock valued at $11,508,000 after buying an additional 900 shares during the period. Finally, Goelzer Investment Management Inc. grew its holdings in shares of Baxter International by 13.6% in the 4th quarter. Goelzer Investment Management Inc. now owns 7,677 shares of the medical instruments supplier’s stock valued at $496,000 after buying an additional 922 shares during the period. 83.12% of the stock is owned by institutional investors.

Baxter International (NYSE:BAX) traded up $0.39 during mid-day trading on Tuesday, reaching $66.83. 1,068,014 shares of the company traded hands, compared to its average volume of 3,451,912. The company has a quick ratio of 2.22, a current ratio of 2.80 and a debt-to-equity ratio of 0.37. Baxter International has a 1 year low of $49.30 and a 1 year high of $72.58. The company has a market cap of $36,400.00, a PE ratio of 51.62, a PEG ratio of 1.90 and a beta of 0.78.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.05. Baxter International had a net margin of 6.79% and a return on equity of 15.12%. The firm had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.77 billion. During the same quarter in the previous year, the company posted $0.57 EPS. Baxter International’s revenue was up 4.9% on a year-over-year basis. equities research analysts anticipate that Baxter International will post 2.78 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://ledgergazette.com/2018/02/16/baxter-international-inc-bax-receives-70-23-average-price-target-from-analysts.html.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Analyst Recommendations for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply